Previous Article | Next Article ![]()
Infect. Immun., 07 1997, 2676-2684, Vol 65, No. 7
C Bergquist, EL Johansson, T Lagergard, J Holmgren and A Rudin
Forty-five volunteers were vaccinated twice intranasally with 10, 100, or
1,000 microg of cholera toxin B subunit (CTB). Blood and nasal and vaginal
secretions were collected before and 1 week after the second vaccination
from all volunteers, and the specific and total immunoglobulin A (IgA) and
IgG titers were determined by enzyme-linked immunosorbent assay. Samples
were also taken 6 months (n = 16) and 1 year (n = 14) after the
vaccination. The 10- and 100-microg doses were well tolerated by the
volunteers, but the 1,000-microg dose induced increased secretions from the
nose and repetitive sneezings for several hours. The CTB-specific serum IgA
and IgG increased 21- and 7-fold, respectively, 1 week after vaccination
with the medium dose and increased 61- and 37-fold, respectively, after the
high dose. In nasal secretions the specific IgA and IgG increased 2- and
6-fold after the medium dose and 2- and 20-fold after the high dose,
respectively. In vaginal secretions the specific IgA and IgG increased 3-
and 5-fold after the medium dose and 56- and 74-fold after the high dose,
respectively. The lowest dose did not induce any significant antibody titer
increases in serum or in secretions. The specific IgA and IgG levels in
secretions were still elevated after 6 months but were decreasing 1 year
after the vaccination. These results show that intranasal vaccination of
humans with CTB induces strong systemic and mucosal antibody responses and
suggest that CTB may be used as a carrier for antigens that induce
protective immunity against systemic as well as respiratory and genital
infections.
Copyright © 1997, American Society for Microbiology
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina
Department of Medical Microbiology and Immunology, Goteborg University, Sweden.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|